¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"exit site infection"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • telomeric site
    ³¡ºÐÀýºÎÀ§
  • apparent infection
    Áõ»ó°¨¿°
  • arthropod-borne infection
    ÀýÁöµ¿¹°¸Å°³°¨¿°
  • asymptomatic infection
    ¹«Áõ»ó°¨¿°
  • aerial infection
    °ø±â°¨¿°, ÈíÀÔ°¨¿°
  • abortive infection
    ºÒ¹ß°¨¿°, ºÒÇö°¨¿°
  • aerobic infection
    À¯»ê¼Ò±Õ°¨¿°, È£±â±Õ°¨¿°
  • aerosol infection
    ºÐ¹«°¨¿°
  • airborne infection
    °ø±â¸Å°³°¨¿°
  • anaerobic infection
    ¹«»ê¼Ò±Õ°¨¿°, Çø±â±Õ°¨¿°
  • community infection
    Áö¿ª°¨¿°
  • concurrent infection
    µ¿½Ã°¨¿°
  • contact infection
    Á¢Ã˰¨¿°
  • contagious infection
    Á¢Ã˰¨¿°, Á¢ÃËÀü¿°
  • cross infection
    ±³Â÷°¨¿°
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • primary infection
    ÀÏÂ÷°¨¿°
  • protozoan infection
    ¿øÃæ°¨¿°
  • secondary infection
    ÀÌÂ÷°¨¿°
  • systemic infection
    Àü½Å°¨¿°
  • vaginal infection
    Áú°¨¿°
  • wound infection
    »ó󰨿°
  • infection route
    °¨¿°°æ·Î
  • infection source
    °¨¿°¿ø, Àü¿°¿ø
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • packaging site
    ²Ù¸®±âºÎÀ§
  • privileged site
    Ưº°°Ý¸®ºÎÀ§
  • receptor site
    ¼ö¿ëüºÎÀ§
  • site
    ºÎÀ§
  • telomeric site
    ¸»´ÜºÎÀ§
  • web site
    À¥½ÎÀÌÆ®
  • abortive infection
    ºÒ¹ß°¨¿°, ºÒÇö°¨¿°
  • aerial infection
    °ø±â°¨¿°, ÈíÀÔ°¨¿°
  • aerobic infection
    È£±â±Õ°¨¿°
  • aerosol infection
    ºÐ¹«°¨¿°
  • airborne infection
    °ø±â°¨¿°, ÈíÀÔ°¨¿°
  • anaerobic infection
    ºñ»ê¼Ò±Õ°¨¿°, Çø±â±Õ°¨¿°
  • apparent infection
    Áõ»ó°¨¿°
  • arthropod-borne infection
    ÀýÁöµ¿¹°¸Å°³°¨¿°
  • asymptomatic infection
    ¹«Áõ»ó°¨¿°
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Coxsackie virus infection
    ÄÛ»èŰ¹ÙÀÌ·¯½º°¨¿°.
  • Denal infection
    Ä¡¾Æ°¨¿°
  • ECHO virus infection
    ¿¡ÄÚ¹ÙÀÌ·¯½º°¨¿°.
  • ECHO virus infection
    ¿¡ÄÚ¹ÙÀÌ·¯½º°¨¿°.
  • Gag antigen in HIV infection
    HIV °¨¿°ÀÇ gag Ç׿ø
  • HIV infection
    HIV °¨¿°
  • HIV infection diagnosis
    HIV °¨¿°Áø´Ü
  • Hemophilus infection
    Çì¸ðÇʷ罺°¨¿°, È£Ç÷±Õ°¨¿°.
  • Infection
    °¨¿°(Êïæø)
  • Klebsiella infection
    Ŭ·¹ºê½Ã¿¤¶ó °¨¿°(Áõ).
  • Marburg virus infection
    ¸¶¸£ºÎ¸£±× ¹ÙÀÌ·¯½º °¨¿°.
  • Marburg virus infection
    ¸¶¸£ºÎ¸£±× ¹ÙÀÌ·¯½º °¨¿°.
  • Marburg virus infection
    ¸¶¸£ºÎ¸£±× ¹ÙÀÌ·¯ ½º°¨¿°.
  • abnormality by infection
    °¨¿°±âÇü
  • abortive infection
    ºÒ¹ß°¨¿°, ºÎÀü°¨¿°
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • binding site
    °áÇÕºÎÀ§.
  • binding site
    °á ÇÕºÎÀ§.
  • combining site
    °áÇÕºÎ(Ì¿ùêÝ»).
  • combining site
    °áÇÕºÎÀ§
  • combining site of antibody
    Ç×üÀÇ °áÇÕºÎ.
  • corporal site
    ÀڱøöÅëÀÓ½Å
  • definitive site
    Âø»óÀÚ¸®
  • donor site
    ±Þ¿©ºÎ.
  • fundic site
    ÀڱùٴÚÀÓ½Å
  • internal ribosomal entry site (IRES)
    ³»ºÎ ¸®º¸¼Ø °áÇÕºÎÀ§
  • mutational site
    (µ¹¿¬)º¯ÀÌÁ¡.
  • packaging site
    ²Ù¸®±âºÎÀ§
  • placental site trophoblastic tumor
    ŹݺÎÂøºÎÀ§ À¶¸ð»óÇǼºÁ¾¾ç
  • privileged site
    Ưº°°Ý¸®ºÎÀ§
  • receptor site
    ¼ö¿ëüºÎÀ§.
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • source of infection
    °¨¿°¿ø
  • spurious infection
    °ÅÁþ°¨¿°
  • zoonotic infection
    Àμö°øÅë°¨¿°
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • aminoacyl-tRNA site
    ¾Æ¹Ì³ë¾Æ½ÇtRNA ÀÚ¸®
  • antibody combining site
    Ç×ü°áÂø(ù÷ô÷Ì¿ó·)ÀÚ¸®
  • antigen binding site
    Ç׿ø°áÇÕ(ù÷ê«Ì¿ùê)ÀÚ¸®
  • AP site
    AP ÀÚ¸®
  • A-site
    AÀÚ¸®
  • attachment site
    ºÎÂø(ݾó·)ÀÚ¸®
  • binding site
    °áÇÕ(Ì¿ùê)ÀÚ¸®
  • catalytic site
    Ã˸Å(õºØÚ)ÀÚ¸®
  • codon recognizing site
    ÄÚµ· ÀνÄ(ìããÛ) ÀÚ¸®
  • combining site
    °áÂø(Ì¿ó·)ÀÚ¸®
  • condensing site
    ÃàÇÕ(õêùê)ÀÚ¸®
  • cos site
    cos ÀÚ¸®
  • donor site
    °ø¿©ÀÚ(Íêæ¨í­) ÀÚ¸® = peptidyl site
  • donor splicing site
    "°ø¿©ÀÚ ½ºÇöóÀÌ½Ì ÀÚ¸®, °ø¿©ÀÚ Àß¶óÀÕ±â ÀÚ¸®, (ÔÒ) splicing junctions"
  • D-site
    D-ÀÚ¸® (ÔÒ) donor site
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • primary infection
    ÀÏÂ÷°¨¿°
  • protozoal infection
    ¿øÃæ°¨¿°
  • puerperal infection
    »ê¿å°¨¿°
  • pyogenic infection
    È­³ó¼º°¨¿°
  • secondary infection
    ÀÌÂ÷°¨¿°, ¼Ó¹ß°¨¿°
  • silent infection
    ¹«Áõ»ó°¨¿°
  • staphylococcal infection
    Æ÷µµ±¸±Õ°¨¿°
  • surgical infection
    ¿Ü°úÀû°¨¿°
  • systemic infection
    Àü½Å¼º°¨¿°(Áõ)
  • viral infection
    ¹ÙÀÌ·¯½º°¨¿°
  • water-borne infection
    ¼öÀμº°¨¿°, ¼öÀμºÀü¿°
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
WOX wound of exit
WX wound of exit
CRI Cardiac Risk Index; catheter-related infection; chronic renal insufficiency; chronic respiratory ins...
GnRH Gonadotropin Releasing Hormone  [HP 1898, 2034]
  = LHRH
  = Go...
CMS children's medical services; Christian Medical Society; chronic myelodysplastic syndrome; chromosome...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
DBP D site binding protein
ESAG expression site-associated gene
HS 2 hypersensitive site 2
GAS IFN-gamma activation site
IGRS Imidazoline-guanidinium-receptive site
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • web site
    À¥½ÎÀÌÆ®
    ÀÎÅͳݿ¡¼­ ¾î¶² Á¤º¸¸¦ Á¦°øÇϰí ÀÖ´Â ÇϳªÀÇ »çÀ̹ö °ø°£. ÀÎÅÍ³Ý ÁÖ¼Ò°¡ °¡¸®Å°´Â °÷.
  • acute HIV infection syndrome
    ±Þ¼º ÀÎü ¸é¿ª °áÇÌ ¹ÙÀÌ·¯½º Áúȯ °¨¿° ÁõÈıº
  • acute periapical infection
    ±Þ¼º Ä¡±Ù´Ü °¨¿°
  • acute Vincent's infection
    ±Þ¼º ºó¼¾Æ®¾¾ ±Ë¾ç¼º °¨¿°, ±Þ¼º ºó¼¾Æ® °¨¿°
  • aerial infection
    °ø±â °¨¿°, ÈíÀÔ °¨¿°
  • aerobic infection
    È£±â±Õ °¨¿°, È£±â±Õ¼º °¨¿°
  • air borne infection
    °ø±â °¨¿°, ÈíÀÔ °¨¿°
  • air-borne infection
    °ø±â ¸Å°³ °¨¿°
  • asymptomatic infection
    Áõ»ó °¨¿°
  • bacterial infection
    ¼¼±Õ °¨¿°, ¼¼±Õ¼º °¨¿°, ¹ÚÅ׸®¾Æ °¨¿°
    ¼¼±Õ¿¡ ÀÇÇÑ °¨¿°. °áÇÙ±Õ°ú °°ÀÌ ¸¸¼º À°¾ÆÁ¾¼º ¿°ÁõÀ» ÀÏÀ¸Å°´Â ÀϺÎÀÇ ¼¼±ÕÀ» Á¦¿ÜÇϰí´Â ´ëºÎºÐ È­³ó¼º ¿°ÁõÀ» ÀÏÀ¸Å°¸ç µå¹°°Ô °æ¸·¿Ü ¶Ç´Â °æ¸·ÇÏ ³ó¾çÀ» Çü¼ºÇϱ⵵ ÇÏÁö¸¸ ´ë°³ È­³ó¼º ¼ö¸·¿°, ±¹¼ÒÀû ³ú¿°, ³ú ³ó¾çÀ» Çü¼ºÇÑ´Ù.
  • bacteroides infection
    ¹ÚÅ×·ÎÀ̵¥½º °¨¿°Áõ
  • candida infection
    ĵµð´Ù °¨¿°
  • candidal infection
    Ä­µð´Ù °¨¿°
  • consecutive infection
    ¼Ó¹ß¼º °¨¿°
  • contact infection
    Á¢ÃË °¨¿°
    º¸±ÕÀÚ, ¶Ç´Â º´¿øÃ¼°¡ ºÎÂøÇÑ ÀǺ¹, ¹°Ç° µî¿¡ Á÷Á¢ ´ê¾Æ ÇǺγª Á¡¸·À¸·Î °¨¿°µÇ´Â Àü¿°º´ÀÇ ÀüÆÄ ¾ç½Ä. ÀÓÁú, ¸Åµ¶, Æ®¶óÄÚ¸¶ µîÀÌ ´ëÇ¥Àû ÁúȯÀÌ´Ù. ȯÀÚ³ª º¸±ÕÀÚÀÇ º´¿øÃ¼°¡ ±âħ, Àçä±â, ´ëÈ­ µîÀ» ÅëÇÏ¿© »ç¶÷ÀÇ ÄÚ³ª ¸ñ±¸¸ÛÀÇ Á¡¸·¿¡ ºñ»ê, ºÎÂøÇÏ¿© °¨¿°À» ÀÏÀ¸Å°´Â ºñ¸» °¨¿°µµ Á¢ÃË °¨¿°¿¡ Æ÷ÇÔ½ÃŲ´Ù. ÀÎÇ÷翣ÀÚ, Æó°áÇÙ µîÀÌ ÀÌ¿¡ ¼ÓÇÑ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
gaylus-site <chemical> A yellowish white, translucent mineral, consisting of the carbonates of lime and soda, with water.
Origin: Named after Gay-Lussac, the French chemist.
(20 Mar 1998)
receptor site Point of attachment of viruses, hormones, or other activators to cell membranes.
(05 Mar 2000)
catalytic site <chemistry> The site on an enzyme where the substrate or substrates (the reactants of a chemical or biochemical reaction) attach in order to convert to the product or products of the reaction, at a much higher speed than the substrate would need to convert to the product alone.
(16 Mar 1998)
replication site The in vivo site on DNA of DNA replication.
(05 Mar 2000)
restriction enzyme cutting site <molecular biology> A specific nucleotide sequence of DNA at which a particular restriction enzyme cuts the DNA.
Some sites occur frequently in DNA (for example, every several hundred basepairs), others much less frequently (rare-cutter, for example, every 10,000 base pairs).
(10 Mar 1998)
restriction site A sequence in DNA that can be recognised and cut by a specific restriction enzyme.
(12 Dec 1998)
restriction-site polymorphism DNA polymorphism in which the sequence of one form of the polymorphism contains a recognition site for a particular endonuclease, but the sequence of the other form lacks such a site.
(05 Mar 2000)
chi site <molecular biology> Short, active sequences of DNA which strongly encourages crossing over of chromosomes to occur at that site. These sites become chiasmata more often than other sites.
(05 Jan 1998)
ribosome binding site The region of a messenger RNA molecule that binds the ribosome to initiate translation.
(09 Oct 1997)
cleavage site A sequence in DNA that can be recognised and cut by a specific restriction enzyme.
(12 Dec 1998)
combining site <biochemistry, immunology> Any region of a molecule that binds or reacts with a given compound. Especially of the region of immunoglobulin that combines with the determinant of an appropriate antigen.
(09 Jan 1998)
placental site trophoblastic tumour A tumour usually arising in the uterus of parous women during reproductive years. Histologically, the tumour consists of a predominance of intermediate trophoblastic cells with fibrinoid material and vascular invasion.
(05 Mar 2000)
Con A binding site <biochemistry> A common misuse of the term receptor. Con A binds to the mannose residues of many different glycoproteins and glycolipids and the binding is therefore not to a specific site.
It could be argued that the receptor is the Con A and cells have Con A ligands on their surfaces: certainly this would be less confusing.
(05 Jan 1998)
multiple cloning site Region of a phage or plasmid vector that has been engineered to contain a series of restriction sites that are usually unique within the entire vector. This makes it particularly easy to insert or excise (subclone) DNA fragments.
(18 Nov 1997)
mutagenesis, site-directed Mutagenesis where the mutation is caused by in vitro induction directed at a specific site in a DNA molecule. The most common method involves use of a chemically synthesised oligonucleotide mutant which can hybridise with the DNA target molecule. The resulting mismatch-carrying DNA duplex may then be transfected into a bacterial cell line and the mutant strands recovered.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • county seat (site)
    ±ºÃ» ¼ÒÀçÁö;±ºÀÇÇàÁ¤ Áß½ÉÁö
  • launching site
    ¹ß»ç±âÁö
  • receptor site
    ¼¼Æ÷³» ¼ö¿ë ¿µ¿ª
  • restriction site
    Á¦ÇÑ ºÎÀ§(Á¦ÇÑ È¿¼Ò°¡ Àý´ÜÇÏ´Â µÎ ÁÙ »ç½½ DNA»óÀÇ ºÎÀ§)
  • site
    À§Ä¡;Àå¼Ò;¿ëÁö;ºÎÁö !
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á